About Roivant Sciences
Roivant Sciences is a publicly listed company based in New York (United States) founded in 2014 by Vivek Ramaswamy. Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. Roivant Sciences has raised $1.3 billion across 4 funding rounds from investors including HHS, RTW Investments and SoftBank Vision Fund. The company has 750 employees. Roivant Sciences has completed 2 acquisitions, including Plexcera Therapeutics and Silicon Therapeutics. Its chief executive, as recorded, is Matthew Gline. Its website roivant.com draws about 23 thousand monthly visits. Roivant Sciences offers products and services including Vants, Immunovant, Priovant, and Pulmovant. Its focus areas include Diversified Pharmaceuticals and Drugs. Its legal entity is Roivant Sciences Ltd. Its competitors include AbbVie, Gilead and Lilly.
Company details
Roivant Sciences is developing therapeutics in disease areas such as neurology, oncology, rare diseases, and endocrinology. Its CNS drug pipeline include Intepirdine, a selective 5-HT6 receptor antagonist for mild-to-moderate Alzheimers disease (phase 3), dementia with Lewy bodies (DLB) (phase 3), gait and balance impairments in dementia (phase 2); Nelotanserin, agonist of the 5-HT2A receptor for visual hallucinations in Lewy body dementia (phase 2), REM behavior disorder (RBD) in DLB (phase 23); RVT-103 and RVT-104 for Alzheimers disease (phase 1) and Lewy body dementia (phase 1). Other drugs in the pipeline include Relugolix for uterine fibroids (phase 3), endometriosis (phase 3) and prostate cancer (phase 3). It is also developing drugs for atopic dermatitis (phase 2), autism (phase 2), female infertility (phase 2) and Farber disease (phase 2).
- Headquarters New York, United States
- Employees 750
- Founders Vivek Ramaswamy
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website roivant.com
- Social LinkedIn X
- Legal Name Roivant Sciences Ltd.
- Annual Revenue$8.26 M (USD)-71.57as on Mar 31, 2026
- Net Profit-$299.77 M (USD)-74.3as on Mar 31, 2026
- EBITDA-$1.26 B (USD)-14.33as on Mar 31, 2026
- Total Equity Funding$1.3B (USD)
in 4 rounds
- Latest Funding Round$200M (USD), Private Equity Round
Nov 2018
- InvestorsHHS
& 5 more
- Employee Count750
- Investments & AcquisitionsPlexcera Therapeutics
& 1 more
Products & Services of Roivant Sciences
Roivant Sciences offers a comprehensive portfolio of products and services, including Vants, Immunovant, Priovant, and Pulmovant.
Platform for creating focused subsidiaries to develop medicines
Subsidiary advancing treatments for autoimmune diseases
Subsidiary targeting severe autoimmune conditions
Subsidiary focused on pulmonary disease treatments
Funding Insights of Roivant Sciences
Roivant Sciences has successfully raised a total of $1.3B across 4 strategic funding rounds. The most recent funding activity was a Private Equity Round of $200 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.3B
- Total Rounds 4
- Last Round Private Equity Round — $200M
- Investors Count 6
All 4 funding rounds of Roivant Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2018 | $200M | Private Equity Round | – | NovaQuest Capital Management | |
| Apr 2018 | $1.43M | Grant | – | – | |
| Aug 2017 | $1.1B | Private Equity Round | – | SoftBank Vision Fund | |
| Dec 2015 | Debt – Conventional | – | – |
6 investors in total: 6 institutional.
Investors in Roivant Sciences
Roivant Sciences has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, RTW Investments and SoftBank Vision Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology and startups. | 2016 | visionfund.com | London, United Kingdom | |
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
PE firm focused on life science and healthcare companies | novaquest.com | Raleigh, United States | ||
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Dexcel Pharma is engaged in developing and commercializing pharmaceuticals. | dexcel.com | Or Akiva, Israel |
Investor details for Roivant Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Roivant Sciences
109 people are tracked at Roivant Sciences (49 in leadership, 19 in board & advisors, 41 in team); the tracked headcount is 750.
| Name | Role | Group |
|---|---|---|
Vivek Ramaswamy | Founder | Leadership |
Matthew Gline | CEO | Leadership |
Gavin Corcoran | Chief R&D Officer, Axovant | Leadership |
Matt Gline | CEO | Leadership |
Harish Soundararajan | Vice President, Investments | Leadership |
Richard Pulik | CFO | Leadership |
Karen Jay | Director | Leadership |
Colin Bower | Chief Commercial Officer, Lokavant | Leadership |
Eric Wasserstrum | Head Of Governance Transactions | Leadership |
Paul T Oppold | VP, Investments | Leadership |
Travis Gibbs | Senior Director, Accounting | Leadership |
Mayukh Sukhatme | President & Chief Investment Officer | Leadership |
Eric Venker | President & COO | Leadership |
Keyur Parekh | Head Of Investor Relations | Leadership |
Tanya Shaby | Partner, Legal | Leadership |
Andrew Bogorad | Head Of Special Projects, Investments | Leadership |
Huafeng Xu | Chief Technology Officer, Roivant Discovery | Leadership |
Jessica Marenco | Associate Director, Accounting Operations | Leadership |
Kelly Graff | Svp, Head Of People | Leadership |
John Alfano | Chief Operating Officer, Lokavant | Leadership |
89 more people are available in the full profile.
Complete people profiles for Roivant Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Roivant Sciences
Roivant Sciences is a publicly listed company on the NASDAQ with ticker symbol ROIV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Oct 2021
- Listed onNASDAQ: ROIV
- Listed entityRoivant Sciences Ltd.
- Exchange sectorHealth technology
- ISINBMG762791017
- Share price$33.35 (-3.58% on the day) · 2026-10-13
- Market capitalisation$24.09B
- EPS (diluted, trailing year)$-0.44
- Volume (last session)6,322,225
Financials of Roivant Sciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $8.3M | -$299.8M | -$1.26B |
| 2024 | $29.1M | -$172.0M | -$1.11B |
| 2023 | $32.7M | $4.35B | -$814.4M |
| 2022 | $61.3M | -$1.01B | -$1.05B |
| 2021 | $55.3M | -$845.3M |
Detailed financial statements for Roivant Sciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Roivant Sciences
Roivant Sciences has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Plexcera Therapeutics and Silicon Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of In-Silico Targeted Engineering platform to build in silico models of human drug targets | silicontx.com | Boston, United States | 2016 | Feb 2021 | $450M | |
Therapeutics for genetic diseases using recombinant acid ceramidase are developed. | plexcera.com | Vero Beach, United States | 2013 | Jul 2016 | •••• |
Complete acquisition details for Roivant Sciences
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Roivant Sciences
6 dated milestones of Roivant Sciences across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Roivant Sciences is founded.
- Funding First funding round.
- Acquisition Acquires Plexcera Therapeutics.
- Funding Latest funding round, Private Equity Round, of $200.0M.
- Acquisition Acquires Silicon Therapeutics.
- IPO Lists on the stock exchange (IPO).
Competitors of Roivant Sciences
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abbvie.com | 2012 | Chicago, United States | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | ||
| gilead.com | 1987 | Foster, United States | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | ||
| lilly.com | 1876 | United States | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. |
Detailed competitors of Roivant Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Roivant Sciences
The website of Roivant Sciences (roivant.com) receives about 22.6K visits a month and ranks #1,359,078 among all websites worldwide, #1,762 in Biotechnology and Pharmaceuticals.
- Monthly visits22.6K
▲ 10% vs previous month
- Unique visitors10.7K
per month
- Global rank#1,359,078
among all websites
- Category rank#1,762
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit1.7
- Average visit40 sec
- DevicesDesktop 45% · Mobile 55%
Websites whose visitors overlap most with Roivant Sciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
lupus.org | lupus.org | 100% | #234,476 | – | |
pulmonaryfibrosis.org | pulmonaryfibrosis.org | 100% | #715,708 | – | |
firstwordpharma.com | firstwordpharma.com | 100% | #237,108 | – | |
| hitconsultant.net | 67% | 680.7K | #747,525 | View details |
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Roivant Sciences (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 | ||
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | USD 65.18 B | 47,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Roivant Sciences
Complete news archive for Roivant Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Roivant Sciences
Roivant Sciences was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Roivant Sciences is headquartered in New York, United States. It is registered at New York, New York, United States.
Matthew Gline is the CEO of Roivant Sciences, as recorded in our data.
Roivant Sciences is a funded company, having raised a total of $1.3B across 4 funding rounds to date.
Roivant Sciences has 750 employees.
Annual revenue of Roivant Sciences is $8.26M as on Mar 31, 2026.
Roivant Sciences is developing therapeutics in disease areas such as neurology, oncology, rare diseases, and endocrinology. Its CNS drug pipeline include Intepirdine, a selective 5-HT6 receptor antagonist for mild-to-moderate Alzheimers disease (phase 3), dementia with Lewy bodies (DLB) (phase 3), gait and balance impairments in dementia (phase 2); Nelotanserin, agonist of the 5-HT2A receptor for visual hallucinations in Lewy body dementia (phase 2), REM behavior disorder (RBD) in DLB (phase 23); RVT-103 and RVT-104 for Alzheimers disease (phase 1) and Lewy body dementia (phase 1). Other drugs in the pipeline include Relugolix for uterine fibroids (phase 3), endometriosis (phase 3) and prostate cancer (phase 3). It is also developing drugs for atopic dermatitis (phase 2), autism (phase 2), female infertility (phase 2) and Farber disease (phase 2).
Roivant Sciences offers Vants, Immunovant, Priovant, and Pulmovant.
Yes, Roivant Sciences is publicly traded on NASDAQ under the ticker symbol ROIV.
Roivant Sciences has made 2 acquisitions, including Plexcera Therapeutics, and Silicon Therapeutics.
Roivant Sciences has 6 investors. Key investors include HHS, RTW Investments, SoftBank Vision Fund, Dexcel Pharma, and Viking Global Investors.